行情

NYMX

NYMX

Nymox
NASDAQ

实时行情|Nasdaq Last Sale

2.140
+0.040
+1.90%
交易中 11:51 04/06 EDT
开盘
2.150
昨收
2.100
最高
2.233
最低
2.080
成交量
2.58万
成交额
--
52周最高
4.090
52周最低
1.320
市值
1.54亿
市盈率(TTM)
-11.1691
分时
5日
1月
3月
1年
5年

NYMX 新闻

更多
  • Nymox Pharmaceutical Corp Files For Mixed Shelf Offering Of Up To $12M
  • Reuters · 2天前
  • Is Nymox Pharmaceutical (NASDAQ:NYMX) In A Good Position To Deliver On Growth Plans?
  • Simply Wall St. · 03/21 15:10
  • Nymox Pharma Highlights New Peer Review Publication Of Its Prostate Cancer Candidate Fexapotide In World Journal Of Urology
  • Benzinga · 02/24 14:31
  • Nymox Announces New Peer Review Publication of Prostate Cancer Fexapotide Clinical Trial Results in World Journal of Urology
  • GlobeNewswire · 02/24 14:30

所属板块

生物技术和医学研究
+3.88%
制药与医学研究
+3.00%

热门股票

代码
价格
涨跌幅

NYMX 简况

Nymox Pharmaceutical Corp is a Canada-based biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company operates through the research and development of products for the aging population segment. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also owns rights for its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex, Inc. conducts research and development, and manufacturing of NicAlert and TobacAlert.
展开

微牛提供Nymox Pharmaceutical Corp(NASDAQ-NYMX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的NYMX股票新闻,以帮助您做出投资决策。